The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Open accessAbstract
Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate. Introduction: Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with stringent dosing instructions that may impair patient compliance and hence therapeutic efficacy. Less frequent, intermittent administration may help to overcome these deficiencies. This study assessed the efficacy and safety of oral ibandronate administered either daily or intermittently with a dose-free interval of >2 months. Materials and Methods: This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score ≤ −2.0 at the lumbar spine in at least one vertebra (L1-L4) and one to four prevalent vertebral fractures (T4-L4). Patients received placebo or oral ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months). Results and Conclusions: After 3 years, the rate of new vertebral fractures was significantly reduced in patients receiving oral daily (4.7%) and intermittent ibandronate (4.9%), relative to placebo (9.6%). Thus, daily and intermittent oral ibandronate significantly reduced the risk of new morphometric vertebral fractures by 62% (p = 0.0001) and 50% (p = 0.0006), respectively, versus placebo. Both treatment groups also produced a statistically significant relative risk reduction in clinical vertebral fractures (49% and 48% for daily and intermittent ibandronate, respectively). Significant and progressive increases in lumbar spine (6.5%, 5.7%, and 1.3% for daily ibandronate, intermittent ibandronate, and placebo, respectively, at 3 years) and hip BMD, normalization of bone turnover, and significantly less height loss than in the placebo group were also observed for both ibandronate regimens. The overall population was at low risk for osteoporotic fractures. Consequently, the incidence of nonvertebral fractures was similar between the ibandronate and placebo groups after 3 years (9.1%, 8.9%, and 8.2% in the daily, intermittent, and placebo groups, respectively; difference between arms not significant). However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score < −3.0). In addition, oral ibandronate was well tolerated. Oral ibandronate, whether administered daily or intermittently with an extended between-dose interval of >2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. This is the first time that significant fracture efficacy has been prospectively shown with an intermittently administered bisphosphonate in the overall study population of a randomized, controlled clinical trial. Thus, oral ibandronate holds promise as an effective and convenient alternative to current bisphosphonate therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Noninvasive assessment of bone mineral and structure: State of the art
Genant, H. K., Engelke, K., Fuerst, T. P., Glüer, C., Grampp, S., Harris, S. T., Jergas, M. D., Lang, T., Lü, Y., Majumdar, S., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110602 · Cited by 948
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sørensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 926
Research works printed but not linked: 4
- Melton, 1991, Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites, J Bone Miner Res, 6, S136
- Kendler, 2002, Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study, Osteoporos Int, 13, S32
- Palmisano, 2002, Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis, Osteoporos Int, 13, S36
- Kiel, 1995, Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures, J Bone Miner Res, 10, 518
Cited by
Sorted by citations
Items 201–300 of 999
Felsenberg, D., Miller, P. D., Armbrecht, G., Wilson, K., Schimmer, R. C., & Papapoulos, S. E. (2005) · Bone · doi:10.1016/j.bone.2005.05.004 · Cited by 78
Self-citationBigi, A., Boanini, E., Capuccini, C., Fini, M., Mihailescu, I. N., Ristoscu, C., Sima, F., & Torricelli, P. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.066 · Cited by 78
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence
Rabenda, V., Hiligsmann, M., & Reginster, J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903140533 · Cited by 78
Blake, G. M., Chinn, D. J., Steel, S. A., Patel, R., Panayiotou, E., Thorpe, J., & Fordham, J. N. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2018-x · Cited by 76
Sanderson, J., James, M. M., Stevens, J., Goka, E., Wong, R., Campbell, F., Selby, P. L., Gittoes, N. J. L., & Davis, S. (2016) · Bone · doi:10.1016/j.bone.2016.05.013 · Cited by 77
Davis, S., James, M. M., Sanderson, J., Stevens, J., Goka, E., Rawdin, A., Sadler, S., Wong, R., Campbell, F., Stevenson, M., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20780 · Cited by 76
An overview on the treatment of postmenopausal osteoporosis
Maeda, S. S., & Lazaretti‐Castro, M. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003039 · Cited by 79
Harris, S. T., Reginster, J., Harley, C., Blumentals, W. A., Poston, S. A., Barr, C. E., & Silverman, S. L. (2009) · Bone · doi:10.1016/j.bone.2009.01.002 · Cited by 75
Treatment of osteoporosis in chronic kidney disease and end-stage renal disease
Miller, P. D. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0021-y · Cited by 74
Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Candelas, G., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.09.004 · Cited by 81
Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions
Curtis, J. R., & Safford, M. M. (2012) · Drugs & Aging · doi:10.2165/11599620-000000000-00000 · Cited by 74
Bone Densitometry and Vertebral Fracture Assessment
Lewiecki, E. M. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0018-z · Cited by 76
Bauer, D. C., Black, D. M., Bouxsein, M., Lui, L., Cauley, J. A., de Papp, A. E., Grauer, A., Khosla, S., McCulloch, C. E., & Eastell, R. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3355 · Cited by 75
Theoretical Implications of the Biomechanical Fracture Threshold
Keaveny, T. M., & Bouxsein, M. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080406 · Cited by 71
Tsai, J. N., Lee, H., David, N. L., Eastell, R., & Leder, B. Z. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30255-4 · Cited by 71
Eastell, R., Vittinghoff, E., Lui, L., McCulloch, C. E., Pavo, I. J., Chines, A. A., Khosla, S., Cauley, J. A., Mitlak, B., Bauer, D. C., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4433 · Cited by 73
Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós‐menopausa
Radominski, S., Bernardo, W. M., de Paula, A. P., Albergaria, B., Moreira, C., Fernandes, C. E., Castro, C. H. D. M., Zerbini, C. A. F., Domiciano, D. S., de Mendonça, L. M. C., et al. (2017) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2017.06.001 · Cited by 75
Diagnosis and management of osteoporosis in the older senior
Vondracek, S. F. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4965 · Cited by 70
Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women
Chapurlat, R. D. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15580903 · Cited by 67
Martial arts fall training to prevent hip fractures in the elderly
Groen, B. E., Smulders, E., de Kam, D., Duysens, J., & Weerdesteyn, V. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0934-x · Cited by 68
Gold, D. T., Martin, B. C., Frytak, J. R., Amonkar, M. M., & Cosman, F. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167615 · Cited by 66
The use of raloxifenein osteoporosis treatment
D’Amelio, P., & Isaia, G. C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.782002 · Cited by 67
Postmenopausal Osteoporosis: A Literature Review
Bhatnagar, A., & Kekatpure, A. L. (2022) · Cureus · doi:10.7759/cureus.29367 · Cited by 79
Bone health and osteoporosis in postmenopausal women
de Villiers, T. J. (2008) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2008.10.009 · Cited by 70
Diacinti, D., & Guglielmi, G. (2010) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2010.02.018 · Cited by 66
Prevention, Screening, and Management of Osteoporosis: An Overview of the Current Strategies
Bonura, F. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2021 · Cited by 66
Current approaches to osteoporosis treatment
Lim, S. Y., & Bolster, M. B. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000169 · Cited by 65
Monitoring osteoporosis treatment
Compston, J. E. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.09.007 · Cited by 64
Hadji, P., Minne, H. W., Pfeifer, M. A., Bourgeois, P., Fardellone, P., Licata, A. A., Devas, V., Masanauskaite, D., & Barrett-Connor, E. L. (2008) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.07.011 · Cited by 63
Fritton, J. C., Myers, E. R., Wright, T. M., & van der Meulen, M. C. H. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080104 · Cited by 63
Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective
Hansen, L., Petersen, K. D., Eriksen, S. A., Langdahl, B. L., Eiken, P., Brixen, K., Abrahamsen, B., Jensen, J. B., Harsløf, T., & Vestergaard, P. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2875-2 · Cited by 63
Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.05.013 · Cited by 66
Quality of Life in Patients with Osteoporotic Vertebral Compression Fractures
Jung, H. J., Park, Y., Seo, H.-Y., Lee, J., An, K.-C., Kim, J.-H., Shin, B.-J., Kang, T. W., & Park, S.-Y. (2017) · Journal of Bone Metabolism · doi:10.11005/jbm.2017.24.3.187 · Cited by 67
Seeman, E., Boonen, S., Borgström, F., Vellas, B. J., Aquino, J., Semler, J., Benhamou, C.-L., Kaufman, J., & Reginster, J. (2009) · Bone · doi:10.1016/j.bone.2009.12.006 · Cited by 63
Functionalization of biomimetic calcium phosphate bone cements with alendronate
Panzavolta, S., Torricelli, P., Bracci, B., Fini, M., & Bigi, A. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.06.008 · Cited by 62
Bisphosphonates for post-menopausal osteoporosis: are they all the same?
Rizzoli, R. (2011) · QJM · doi:10.1093/qjmed/hcq259 · Cited by 61
Mori, H., Tanaka, M., Kayasuga, R., Masuda, T., Ochi, Y., Yamada, H., Kishikawa, K., Ito, M., & Nakamura, T. (2008) · Bone · doi:10.1016/j.bone.2008.07.242 · Cited by 62
Lambrinoudaki, I. V., Christodoulakos, G., & Botsis, D. S. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1365.036 · Cited by 62
Manske, S. L., Liu-Ambrose, T. Y. L., de Bakker, P. M., Liu, D., Kontulainen, S. A., Guy, P., Oxland, T. R., & McKay, H. A. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0162-6 · Cited by 61
Prevrhal, S., Krege, J. H., Chen, P., Genant, H. K., & Black, D. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902790993 · Cited by 61
McGee‐Lawrence, M. E., Carey, H. V., & Donahue, S. W. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90648.2008 · Cited by 63
Gehrig, L. M. B., Lane, J., & O’Connor, M. I. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200806000-00028 · Cited by 61
Safety issues and adverse reactions with osteoporosis management
Rossini, M., Adami, G., Adami, S., Viapiana, O., & Gatti, D. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1136287 · Cited by 60
Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis
Cummings, S. R., Martín, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P. D., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000363236.41902.96 · Cited by 62
Self-citationThe treatment gap: The missed opportunities for osteoporosis therapy
Fuggle, N. R., Curtis, E. M., Clynes, M. A., Zhang, J., Ward, K. A., Javaid, M. K., Harvey, N. C., Dennison, E. M., & Cooper, C. C. (2020) · Bone · doi:10.1016/j.bone.2020.115833 · Cited by 62
Long-term consequences of osteoporosis therapy with bisphosphonates
Gehrke, B., Coelho, M. C. A., d’Alva, C. B., & Madeira, M. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2022-0334 · Cited by 58
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
Miller, P. D., Recker, R. R., Reginster, J.-Y., Riis, B. J., Czerwinski, E. J., Masanauskaite, D., Kenwright, A., Lorenc, R. S., Stakkestad, J. A., & Lakatos, P. L. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1773-0 · Cited by 58
Self-citationFor the MOVER Study Group, Nakamura, T., Nakano, T., Ito, M., Hagino, H., Hashimoto, J., Tobinai, M., & Mizunuma, H. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9734-6 · Cited by 58
Management of atypical femoral fracture: a scoping review and comprehensive algorithm
Toro, G., Ojeda‐Thies, C., Calabrò, G., Toro, G., Moretti, A., Guerra, G., Caba-Doussoux, P., & Iolascon, G. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1086-8 · Cited by 58
Dimai, H. P., & Fahrleitner‐Pammer, A. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101780 · Cited by 58
Treatment Sequence for Osteoporosis
Cosman, F., Langdahl, B. L., & Leder, B. Z. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.01.014 · Cited by 62
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
Carbonare, L. D., Zanatta, M., Gasparetto, A., & Valenti, M. T. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6285 · Cited by 57
Effects of bisphosphonates on osteoporosis: Focus on zoledronate
Oryan, A., & Sahvieh, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118681 · Cited by 58
Current, new and future treatments of osteoporosis
Salari, P., Abdollahi, M. R., & Larijani, B. A. (2010) · Rheumatology International · doi:10.1007/s00296-010-1586-z · Cited by 55
Medication Persistence With Weekly Versus Daily Doses of Orally Administered Bisphosphonates
Ettinger, M. P., Gallagher, R., & MacCosbe, P. E. (2006) · Endocrine Practice · doi:10.4158/ep.12.5.522 · Cited by 56
Long-Term Effect of Strontium Ranelate Treatment on BMD
Blake, G. M., & Fogelman, I. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050810 · Cited by 58
Treatment of osteoporosis after alendronate or risedronate
Eiken, P., & Vestergaard, P. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3334-4 · Cited by 54
Bianchi, G., Czerwinski, E. J., Kenwright, A., Burdeska, A., Recker, R. R., & Felsenberg, D. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1793-9 · Cited by 54
Self-citationBisphosphonate Therapeutics in Bone Disease: The Hard and Soft Data on Osteoclast Inhibition
Drake, M. T., & Cremers, S. C. L. M. (2010) · Molecular Interventions · doi:10.1124/mi.10.3.5 · Cited by 61
Camm, A. J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.014 · Cited by 52
Management of Spinal Deformities and Evidence of Treatment Effectiveness
Bettany‐Saltikov, J., Turnbull, D. A., Ng, S. Y., & Webb, R. (2017) · The Open Orthopaedics Journal · doi:10.2174/1874325001711011521 · Cited by 54
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis
Iwamoto, J., Takeda, T., & Satō, Y. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x100276 · Cited by 53
Oral bisphosphonate use in the elderly is not associated with acute kidney injury
Shih, A. W. Y., Weir, M. A., Clemens, K. K., Yao, Z., Gomes, T., Mamdani, M., Juurlink, D. N., Hird, A. E., Hodsman, A. B., Parikh, C. R., et al. (2012) · Kidney International · doi:10.1038/ki.2012.227 · Cited by 53
Blake, G. M., & Fogelman, I. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.367 · Cited by 53
Do bisphosphonates inhibit direct fracture healing?
Savaridas, T., Wallace, R. J., Salter, D. M., & Simpson, H. (2013) · The Bone & Joint Journal · doi:10.1302/0301-620x.95b9.31562 · Cited by 53
Pazianas, M., Blumentals, W. A., & Miller, P. D. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0502-1 · Cited by 53
Reginster, J., Wilson, K., Dumont, E., Bonvoisin, B., & Barrett, J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1750 · Cited by 53
Efficacy and safety of currently marketed anti-osteoporosis medications
Reginster, J., Neuprez, A., Dardenne, N., Beaudart, C., Emonts, P., & Bruyère, O. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.003 · Cited by 53
The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis
Szulc, P. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.01.022 · Cited by 56
Anti-resorptives in the management of osteoporosis
Miller, P. D. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.004 · Cited by 51
Kendler, D. L., Compston, J. E., CAREY, J. J., Wu, C., Ibrahim, A., & Lewiecki, E. M. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.07.010 · Cited by 53
Jin, Y., Lee, J. H., Xu, B., & Cho, M. (2019) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-019-2769-8 · Cited by 52
Review of osteoporosis pharmacotherapy for geriatric patients
Gates, B. J., Sonnett, T. E., DuVall, C. A. K., & Dobbins, E. K. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.12.004 · Cited by 51
Zhang, L., Pang, Y., Shi, Y., Xu, M., Xu, X., Ju, Z., Ji, L., & Zhao, D. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000466 · Cited by 52
Gold, D. T., Alexander, I. M., & Ettinger, M. P. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g534 · Cited by 52
Hara, K., Suda, T., Suda, J., Eguchi, M., Ihle, J. N., Nagata, S., Miura, Y., & Saito, M. (1988) · PubMed · Cited by 51
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch35 · Cited by 51
In VitroEffects of Strontium on Proliferation and Osteoinduction of Human Preadipocytes
Nardone, V., Zonefrati, R., Mavilia, C., Romagnoli, C., Ciuffi, S., Fabbri, S., Palmini, G., Galli, G., Tanini, A., & Brandi, M. L. (2015) · Stem Cells International · doi:10.1155/2015/871863 · Cited by 50
Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis
Lewiecki, E. M. (2009) · Journal of Women s Health · doi:10.1089/jwh.2008.1086 · Cited by 49
Decreased bone mineral density and periodontal management
Reddy, M. S., & Morgan, S. L. (2012) · Periodontology 2000 · doi:10.1111/j.1600-0757.2011.00400.x · Cited by 51
The Diagnosis and Treatment of Osteoporosis
Moon, J. S., & Won, K. C. (2008) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2008.25.1.19 · Cited by 50
Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-Analysis
Albert, S. G., & Reddy, S. (2017) · Endocrine Practice · doi:10.4158/ep161678.ra · Cited by 50
Drug Insight: existing and emerging therapies for osteoporosis
Mulder, J. E., Kolatkar, N. S., & LeBoff, M. S. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0325 · Cited by 51
Bone Physiology, Disease and Treatment
Post, T. M., Cremers, S. C. L. M., Kerbusch, T., & Danhof, M. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318150-000000000-00000 · Cited by 52
Brent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 52
A Comprehensive Review on Postmenopausal Osteoporosis in Women
Charde, S. H., Joshi, A., & Raut, J. M. (2023) · Cureus · doi:10.7759/cureus.48582 · Cited by 62
Treatment of primary osteoporosis in men
Bianchi, G., & Giusti, A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s44057 · Cited by 54
John, M. R., Widler, L., Gamse, R., Buhl, T., Seuwen, K., Breitenstein, W., Bruin, G. J. M., Belleli, R., Klickstein, L. B., & Kneissel, M. (2011) · Bone · doi:10.1016/j.bone.2011.04.007 · Cited by 49
Boonen, S., Vanderschueren, D., Venken, K., Milisen, K., Delforge, M., & Haentjens, P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02010.x · Cited by 50
Adverse drug reactions to osteoporosis treatments
Rizzoli, R., & Reginster, J. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.42 · Cited by 50
Wilkes, M. M., Navickis, R. J., Chan, W. W., & Lewiecki, E. M. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0991-1 · Cited by 49
NOFSA Guideline for the Diagnosis and Management of Osteoporosis
Hough, S. F., Ascott-Evans, B. H., Brown, S. L., Cassim, B., de Villiers, T. J., Lipschitz, S., Pettifor, J. M., & Sonnendecker, E. W. W. (2010) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2010.10872239 · Cited by 48
Gravitational and Space Biology
Landis, W. J. (2005) · Cited by 48
Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis
Songpatanasilp, T., Sritara, C., Kitisomprayoonkul, W., Chaiumnuay, S., Nimitphong, H., Charatcharoenwitthaya, N., Pongchaiyakul, C., Namwongphrom, S., Kitumnuaypong, T., Srikam, W., et al. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.10.002 · Cited by 50
Liberman, U. A., Hochberg, M. C., Geusens, P., SHAH, A., Lin, J. T., Chattopadhyay, A., & Ross, P. D. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01148.x · Cited by 49
Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk
Eastell, R., Vittinghoff, E., Lui, L., Ewing, S. K., Schwartz, A. V., Bauer, D. C., Black, D. M., & Bouxsein, M. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4697 · Cited by 48
Cooper, C. C., Reginster, J., Cortet, B., Díaz Curiel, M., Lorenc, R. S., Kanis, J. А., & Rizzoli, R. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.663750 · Cited by 47
Migliaccio, S., Brama, M., & Spera, G. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.55 · Cited by 47
Update on Osteoporosis Management in Long-term Care: Focus on Bisphosphonates
Kamel, H. K. (2007) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2007.06.005 · Cited by 47
Rud, B., Hilden, J., Hyldstrup, L., & Hróbjartsson, A. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0319-3 · Cited by 46
Metadata
- Authors
- Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., Delmas, P. D., & (BONE), F. T. O. I. O. V. F. T. I. N. A. A. E.
- Affiliations
- University of Washington (US)
- Center for Clinical Trials, Bergen, Norway
- Center for Clinical & Basic Research (DK)
- Creighton University (US)
- CECOR AS, Haugesund, Norway
- Oslo Department, Sentrum Røntgen Institut AS, Oslo, Norway
- Universitatsklinikum Benjamin Franklin, Berlin, Germany
- Leverkusen, Germany
- Roche (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Lyon 1 Université (FR)
- Corresponding author
- Chesnut, Charles H
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 19
- Issue
- 8
- Pages
- 1241-1249
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2099054178
- Cited by
- 1,229
- References
- 42
- Citations by year
- 2026: 14 · 2025: 38 · 2024: 20 · 2023: 42 · 2022: 31 · 2021: 37 · 2020: 35 · 2019: 32 · 2018: 32 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 45 · 2013: 63 · 2012: 62
- FWCI
- 85.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- ibandronate, intermittent dosing, bisphosphonates, postmenopausal osteoporosis, vertebral fractures, fracture risk reduction, bone mineral density, bone turnover, height loss, drug safety, medication adherence, lumbar spine, hip bone density, antifracture efficacy, treatment discontinuation, adverse events
- MeSH terms
- Ibandronic Acid, Aged, Body Height, Bone and Bones, Diphosphonates, Double-Blind Method, Female, Femur, Humans, Lumbar Vertebrae, Middle Aged, Pelvic Bones, Prospective Studies, Risk Factors, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Patient Selection, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
